WEDGE(SZ:000534) Sou Hu Cai Jing·2025-08-25 11:30Core Viewpoint - Wanze Co., Ltd. has shown positive financial performance with significant revenue and profit growth in the latest half-year report, indicating a strong operational capacity in the pharmaceutical manufacturing sector [1]. Financial Performance - As of the latest mid-year report, the company reported total revenue of 625 million yuan, representing a year-on-year growth of 24.40% [1]. - The net profit attributable to shareholders reached 119 million yuan, with a year-on-year increase of 21.84% [1]. - The company's net profit after deducting non-recurring gains and losses was 110 million yuan, reflecting a growth of 29.28% year-on-year [1]. - The liquidity ratios are as follows: current ratio at 1.278 and quick ratio at 0.854, indicating a stable liquidity position [1]. - The asset-liability ratio stands at 59.38%, suggesting a moderate level of financial leverage [1]. Market Activity - As of August 25, 2025, Wanze Co., Ltd. shares closed at 17.06 yuan, with an increase of 0.95% [1]. - The trading volume was 263,600 hands, with a total transaction value of 447 million yuan [1]. - The main capital flow indicated a net outflow of 13.35 million yuan, accounting for 2.99% of the transaction value [1]. - Large orders showed a net outflow of 33.45 million yuan, representing 7.48% of the transaction value, while large orders had a net inflow of 20.10 million yuan, accounting for 4.5% [1]. Company Background - Wanze Co., Ltd. was established in 1992 and is located in Shantou City, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of approximately 500.71 million yuan and a paid-in capital of 62 million yuan [1][2]. - The legal representative of the company is Huang Zhengguang [1].